1. Home
  2. AWF vs TBPH Comparison

AWF vs TBPH Comparison

Compare AWF & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alliancebernstein Global High Income Fund

AWF

Alliancebernstein Global High Income Fund

HOLD

Current Price

$10.09

Market Cap

868.3M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.29

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AWF
TBPH
Founded
1993
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
868.3M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AWF
TBPH
Price
$10.09
$16.29
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$18.40
AVG Volume (30 Days)
414.7K
344.7K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
7.57%
N/A
EPS Growth
N/A
279.13
EPS
N/A
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.85
$10.42
52 Week High
$11.43
$21.03

Technical Indicators

Market Signals
Indicator
AWF
TBPH
Relative Strength Index (RSI) 40.03 50.69
Support Level $9.98 $16.07
Resistance Level $10.24 $17.21
Average True Range (ATR) 0.09 0.32
MACD -0.01 -0.02
Stochastic Oscillator 33.73 72.57

Price Performance

Historical Comparison
AWF
TBPH

About AWF Alliancebernstein Global High Income Fund

Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: